New hope for blood cancer patients: tazemetostat under Real-World study
NCT ID NCT07282548
First seen Jan 09, 2026 · Last updated May 14, 2026 · Updated 15 times
Summary
This study aims to see how well the drug tazemetostat works in adults with a slow-growing blood cancer called follicular lymphoma that has come back or not responded to at least two prior treatments. Participants will take tazemetostat as prescribed by their doctor in routine care. Researchers will track tumor response, how long benefits last, and any side effects. The study was withdrawn before enrolling any participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.